DelveInsight's, "Myocardial Infarction Pipeline Insight, 2022," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Myocardial Infarction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Myocardial Infarction Pipeline Report *DelveInsight's Myocardial Infarction pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Myocardial Infarction treatment. *The leading Myocardial Infarction Companies such as CSL Behring, Idorsia, TRPHARM, ProSTEM, Ever Supreme Bio Technology Co., Ltd., Faraday Pharmaceuticals, Athera Biotechnologies, CeleCor Therapeutics, BIOCARDIA, INC., Beijing Northland Biotech, Olatec Therapeutics, and others are developing potential drug candidates to improve the Myocardial Infarction treatment scenario. *The promising Myocardial Infarction therapies such as abciximab, BioMonitor, RPH-104 80 mg, Metoprolol- Toprol XL, AO Therapy (aqueous oxygen), Aliskiren, Vitalscan, and others. *This segment of the Myocardial Infarction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Latest Breakthroughs and Developments in the Myocardial Infarction Treatment Landscape *In June 2021, Idorsia Ltd (SIX: IDIA) declared the commencement of the Phase 3 registration study "SOS-AMI" to assess the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia's P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI). *Currently, ProSTEM collaborates with Cipto Mangunkusumo Hospital and Medistra to conduct a clinical trial, "Allogeneic Stem Cell Therapy from Cord Tissue for Acute Myocardial Infarction." *Umbilical cord mesenchymal stem cells (UMC01) by Ever Supreme Bio Technology Co., Ltd., for treating acute myocardial infarction (AMI) Phase the FDA approved I clinical trial in February 2018, and by TFDA in September of the same year for entering clinical trials; an investigation new drug research for treating stroke by stem cells via intravenous injection (IV) was also approved by the FDA for Phase I clinical-go in September 2018. Also, the TFDA Phase I clinical-go in March of 2020. *In March 2021, Faraday Pharmaceuticals, Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing a potentially life-changing critical illness, announced that it had reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) on the protocol design and statistical analysis approach to be taken in Faraday's Phase 3 cardiovascular outcomes study evaluating FDY-5301 for the treatment of acute ST-segment elevation myocardial infarction (STEMI) in patients undergoing percutaneous intervention (PCI). *Dapansutrile (Olatec Therapeutics) has been observed to have anti-inflammatory properties and other promising activity in a broad spectrum of over 20 preclinical animal models, including arthritis, asthma, acute myocardial infarction (AMI), contact dermatitis, multiple sclerosis, melanoma and breast cancers, spinal cord injury (SCI) and Alzheimer's disease. *ATH3G10 is a first-in-class fully human antibody to target phosphorylcholine (PC), the head group of oxidized phospholipids (oxPLs), and an epitope on damaged or stressed cells. The candidate is initially being developed for patients with a large ST-elevation myocardial infarction (STEMI) who are at a high risk of heart failure.
Get an overview of the pipeline landscape @ Myocardial Infarction Clinical Trials Analysis
Myocardial Infarction Overview
Myocardial Infarction (MI) is a term used for an event of heart attack which is due to formation of plaques in the interior walls of the arteries resulting in reduced blood flow to the heart and injuring heart muscles because of lack of oxygen supply. The symptoms of MI include chest pain, which travels from left arm to neck, shortness of breath, sweating, nausea, vomiting, abnormal heart beating, anxiety, fatigue, weakness, stress, depression, and other factors. The immediate treatment of MI include, taking aspirin, which prevents blood from clotting, and nitro-glycerin to treat chest pain and oxygen. The heart attack can be prevented by taking an earlier action to lower those risks by controlling diet, fat, cholesterol, salt, smoking, nicotine, alcohol, drugs, monitoring of blood pressure every week, doing exercise every day, and loosing body weight. The treatment of MI includes, aspirin tablets, and to dissolve arterial blockage injection of thrombolytic or clot dissolving drugs such as tissue plasminogen activator, streptokinase or urokinase in blood within 3 h of the onset of a heart attack.
Myocardial Infarction Emerging Drugs *Dapagliflozin: AstraZeneca *Remestemcel-L: Mesoblast
Myocardial Infarction Pipeline Therapeutics Analysis
There are approx. 50+ key companies which are developing the therapies for Myocardial Infarction. The companies which have their Myocardial Infarction drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
For further information, refer to the detailed report @ Myocardial Infarction Emerging Therapies
Scope of the Myocardial Infarction Pipeline Report *Coverage- Global *Myocardial Infarction Companies- CSL Behring, Idorsia, TRPHARM, ProSTEM, Ever Supreme Bio Technology Co., Ltd., Faraday Pharmaceuticals, Athera Biotechnologies, CeleCor Therapeutics, BIOCARDIA, INC., Beijing Northland Biotech, Olatec Therapeutics, and others *Myocardial Infarction Therapies- abciximab, BioMonitor, RPH-104 80 mg, Metoprolol- Toprol XL, AO Therapy (aqueous oxygen), Aliskiren, Vitalscan, and others *Myocardial Infarction Therapeutic Assessment by Product Type *Myocardial Infarction Therapeutic Assessment by Stage and Product Type *Myocardial Infarction Therapeutic Assessment by Route of Administration *Myocardial Infarction Therapeutic Assessment by Stage and Route of Administration *Myocardial Infarction Therapeutic Assessment by Molecule Type *Myocardial Infarction Therapeutic Assessment by Stage and Molecule Type *Myocardial Infarction companies' collaborations, Licensing, Acquisition -Deal Value Trends *Myocardial Infarction - Market Drivers and Barriers
Table of Content *Introduction *Executive Summary *Myocardial Infarction: Overview *Pipeline Therapeutics *Therapeutic Assessment *Myocardial Infarction - DelveInsight's Analytical Perspective *In-depth Commercial Assessment *Myocardial Infarction Collaboration Deals *Late Stage Products (Phase III) *Dapagliflozin: AstraZeneca *Mid Stage Products (Phase II) *Remestemcel-L: Mesoblast *Inactive Products *Myocardial Infarction Key Companies *Myocardial Infarction Key Products *Myocardial Infarction- Unmet Needs *Myocardial Infarction- Market Drivers and Barriers *Myocardial Infarction- Future Perspectives and Conclusion *Myocardial Infarction Analyst Views *Myocardial Infarction Key Companies *Appendix
Got Queries? Reach out for more information on the Myocardial Infarction Pipeline Report- Myocardial Infarction Pipeline Therapeutic Assessment
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
IDORSIA LTD 
